This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Reprints, Permissions and Rights Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Baniwal, S. K. Articles by Frenkel, B. Search for Related Content PubMed PubMed Citation Articles by Baniwal, S. K. Articles by Frenkel, B.

Repression of Runx2 by Androgen Receptor (AR) in Osteoblasts and Prostate Cancer Cells: AR Binds Runx2 and Abrogates Its Recruitment to DNA

Departments of Biochemistry and Molecular Biology (S.K.B., B.F.), Orthopedic Surgery (B.F.), Preventive Medicine (G.B., G.A.C.), Urology (O.K., G.B., G.A.C.), and Molecular Microbiology and Immunology (D.S.), Norris Cancer Center (O.K., G.B., G.A.C.) and Institute of Genetic Medicine (S.K.B., B.F.), Keck School of Medicine, University of Southern California, Los Angeles, California 90033; and Freemasons Foundation Centre for Men’s Health (G.B.), School of Medicine, The University of Adelaide/Hanson Institute, Adelaide, South Australia 5005, Australia

Address all correspondence and requests for reprints to: Baruch Frenkel, D.M.D., Ph.D., Departments of Orthopedic Surgery and Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Institute for Genetic Medicine, 2250 Alcazar Street, CSC 240, Los Angeles, California 90033. E-mail: frenkel{at}usc.edu.

Runx2 and androgen receptor (AR) are master transcription factors with pivotal roles in bone metabolism and prostate cancer (PCa). We dissected AR-mediated repression of Runx2 in dihydrotestosterone (DHT)-treated osteoblastic and PCa cells using reporter assays and endogenous Runx2 target genes. Repression required DHT, but not AR’s transactivation function, and was associated with nuclear colocalization of the two proteins. Runx2 and AR coimmunoprecipitated and interacted directly in glutathione-S-transferase pull-down assays. Interaction was ionic in nature. Intact AR DNA-binding domain (DBD) was necessary and sufficient for both interaction with Runx2 and its repression. Runx2 sequences required for interaction were the C-terminal 132 amino acid residues together with the Runt DBD. Runx2 DNA binding was abrogated by endogenous AR in chromatin immunoprecipitation assays and by recombinant AR-DBD in gel shift assays. Furthermore, AR caused increased nuclear mobility of Runx2 as indicated by faster fluorescence recovery after photobleaching. Thus, AR binds Runx2 and abrogates its binding to DNA and possibly to other nuclear components. Clinical relevance of our results was suggested by an inverse correlation between expression of AR-responsive prostate-specific antigen and osteocalcin genes in PCa biopsies. Given the tumor suppressor properties of Runx2, its repression by AR may constitute a mechanism of hormone carcinogenesis. Attenuation of Runx2 by AR in osteoblasts may play a role in skeletal metabolism: the bone-sparing effect of androgens is attributable, in part, to keeping Runx2 activity in check and preventing high-turnover bone disease such as seen after castration and in transgenic mice overexpressing Runx2 in osteoblasts.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR

Ligands:   Dihydrotestosterone